Shuttle Pharmaceuticals Holdings, Inc. (SHPH): Nasdaq/NYSE listing notice — Shuttle Pharma raises $5.75M in public offering, regains Nasdaq equity compliance

Shuttle Pharmaceuticals Holdings, Inc.

Closed underwritten offering of 1.34M shares and 17.8M pre-funded warrants at $0.30/share, net proceeds ~$5.2M.
Net proceeds to fund Phase II trial of Ropidoxuridine, $2.8M to CRO Theradex, plus up to $2.0M for marketing.
Believes it has regained compliance with Nasdaq minimum stockholders' equity rule of $2.5M after offering.
Offering was sole-underwritten by WestPark Capital; closed March 13, 2025.
Previously received Nasdaq deficiency notice on Sep 10, 2024; plan accepted Nov 26, 2024.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

September 10, 2024, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was no longer in compliance with Nasdaq Rule 5550(b)(1), the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq (the “Minimum Equity Requirement”). In response to the Notice, the Company submitted its plan of regain compliance to Nasdaq (the “Plan”) and on November 26, 2024, the Company received notice from Nasdaq that it had accepted the Plan. In accordance with the Plan, the Company is required to complete a

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-010211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.